Actively Recruiting
Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of IMM-H014 Plus Food Effects in Healthy Adults
Led by Changchun Intellicrown Pharmaceutical Co. LTD · Updated on 2025-04-11
138
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of IMM-H014, an oral drug, in healthy adults aged 18 to 45 years. The trial focuses on how the drug behaves in the body when taken on an empty stomach and after a high-fat, high-calorie meal. This randomized, double-blind, placebo-controlled phase 1 study includes three parts single ascending dose, multiple ascending dose, and food effect evaluation. Participants will receive IMM-H014 or a placebo tablet orally once daily under fasting conditions. The single ascending dose part tests increasing doses from 12.5 mg up to 325 mg in different groups. The multiple ascending dose part involves daily doses for seven days, ranging from 37.5 mg to 225 mg. The food effect part studies the drugs pharmacokinetics after fasting and after a high-fat meal, with a seven-day washout period between treatments. Throughout the study, participants will undergo monitoring for adverse events, physical exams, vital signs, ECGs, and laboratory tests. Researchers will measure drug levels in the blood and observe any changes from baseline. The primary outcomes include safety and tolerability up to about 18 days depending on the study part. Participation will last up to 18 days, including dosing and follow-up assessments.
CONDITIONS
Brief Title
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
Research Team
S
Shiqi Bai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here